In an effort to further educate himself and increase the firm's knowledge in the area, Bahe Cook Cantley & Nefzger PLC partner Will Nefzger attended an American Association for Justice seminar on the emerging Testosterone Replacement Therapy (TRT) Litigation. The seminar offered a thorough examination of the history of the drug, the marketing, the science behind the dangerous side effects, the possible causes of action and the potential defenses by the drug makers.
The overarching theme that arises when examining this drug and its history is that the drug makers essentially created the disease now known as low T. While the drug initially gained approval to treat real medical conditions, like hypogonadism, the pharmaceutical industry began a marketing blitz targeting men who did not necessarily have the medical condition, but were experiencing tiredness, grumpiness, loss of sexual drive and other "symptoms."
The problem is that now studies are showing that the TRT drugs have far more of increased risks than the drug makers have ever warned of, including heart attacks, strokes and severe, life-threatening blood clots. We continue to evaluate and accept these cases.